Bioheng

BioHeng is a clinical biopharmaceutical and biotechnology Company focuses on novel immunotherapy and next-generation gene therapy development for treating cancers and various diseases. Founded in 2017, Bioheng has established a high standard GMP grade clinical translational center, and is leading in the field of cell engineering, proliferation and clinical applications. Particularly, Bioheng owns several cutting-edge patents plus extensive industry experience, and has built a complete, closed and automated production system in compliance with regulatory guidelines.

In 2018, Bioheng has successfully raised tens of millions of RMB seeding fund from Simcere Pharmaceutical Group, aiming to accelerate the development of immunotherapy via integrating resources from both parties. Bioheng is dedicated to develop safer, effective and less expensive cell therapy drugs to benefit more patients.

Bioheng headquartered in Asia, operates in the Biotechnology, Health Care, Biopharma, Innovation Management, Clinical Trials sector. The company focuses on Biotechnology and has secured $3.8B in funding across 40 round(s). With a team of 101-250 employees, Bioheng is actively contributing to advancements in Biotechnology. Their latest funding round, Series B - Bioheng, raised $79.7M. Discover more about their projects, partnerships, and impact on our platform.